JP2016504040A5 - - Google Patents

Download PDF

Info

Publication number
JP2016504040A5
JP2016504040A5 JP2015551870A JP2015551870A JP2016504040A5 JP 2016504040 A5 JP2016504040 A5 JP 2016504040A5 JP 2015551870 A JP2015551870 A JP 2015551870A JP 2015551870 A JP2015551870 A JP 2015551870A JP 2016504040 A5 JP2016504040 A5 JP 2016504040A5
Authority
JP
Japan
Prior art keywords
chromatography
asa
purified recombinant
protein
ultrafiltration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015551870A
Other languages
English (en)
Japanese (ja)
Other versions
JP6427502B2 (ja
JP2016504040A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/010856 external-priority patent/WO2014110246A1/en
Publication of JP2016504040A publication Critical patent/JP2016504040A/ja
Publication of JP2016504040A5 publication Critical patent/JP2016504040A5/ja
Application granted granted Critical
Publication of JP6427502B2 publication Critical patent/JP6427502B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015551870A 2013-01-09 2014-01-09 アリールスルファターゼaの精製方法 Active JP6427502B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361750693P 2013-01-09 2013-01-09
US61/750,693 2013-01-09
PCT/US2014/010856 WO2014110246A1 (en) 2013-01-09 2014-01-09 Methods for purification of arylsulfatase a

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018122837A Division JP2018171067A (ja) 2013-01-09 2018-06-28 アリールスルファターゼaの精製方法

Publications (3)

Publication Number Publication Date
JP2016504040A JP2016504040A (ja) 2016-02-12
JP2016504040A5 true JP2016504040A5 (enExample) 2017-02-16
JP6427502B2 JP6427502B2 (ja) 2018-11-21

Family

ID=50002885

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2015551870A Active JP6427502B2 (ja) 2013-01-09 2014-01-09 アリールスルファターゼaの精製方法
JP2018122837A Withdrawn JP2018171067A (ja) 2013-01-09 2018-06-28 アリールスルファターゼaの精製方法
JP2019174155A Withdrawn JP2020015750A (ja) 2013-01-09 2019-09-25 アリールスルファターゼaの精製方法
JP2021183082A Active JP7407161B2 (ja) 2013-01-09 2021-11-10 アリールスルファターゼaの精製方法
JP2023173170A Active JP7663649B2 (ja) 2013-01-09 2023-10-04 アリールスルファターゼaの精製方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2018122837A Withdrawn JP2018171067A (ja) 2013-01-09 2018-06-28 アリールスルファターゼaの精製方法
JP2019174155A Withdrawn JP2020015750A (ja) 2013-01-09 2019-09-25 アリールスルファターゼaの精製方法
JP2021183082A Active JP7407161B2 (ja) 2013-01-09 2021-11-10 アリールスルファターゼaの精製方法
JP2023173170A Active JP7663649B2 (ja) 2013-01-09 2023-10-04 アリールスルファターゼaの精製方法

Country Status (12)

Country Link
US (3) US11407984B2 (enExample)
EP (1) EP2943568B1 (enExample)
JP (5) JP6427502B2 (enExample)
CN (4) CN112126634A (enExample)
AU (3) AU2014205441B2 (enExample)
BR (1) BR112015015948B1 (enExample)
CA (1) CA2896979C (enExample)
EA (1) EA030551B1 (enExample)
ES (1) ES2768261T3 (enExample)
HK (1) HK1214622A1 (enExample)
MX (2) MX372711B (enExample)
WO (1) WO2014110246A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10336992B2 (en) 2011-07-08 2019-07-02 Shire Human Genetic Therapies, Inc. Methods for purification of arylsulfatase A
CN112126634A (zh) 2013-01-09 2020-12-25 夏尔人类遗传性治疗公司 含用于纯化芳基硫酸酯酶a的方法
EP3236772A4 (en) * 2014-12-22 2018-10-17 Alexion Pharmaceuticals, Inc. Methods of purifying recombinant proteins
KR20180048731A (ko) * 2015-08-20 2018-05-10 제넨테크, 인크. 재조합 폴리펩티드를 제조하기 위한 fkpa의 정제 및 그의 용도
MX2018011162A (es) * 2016-03-16 2018-11-22 Phoenix Tissue Repair Inc Metodos de purificacion de colageno 7.
EP3676375A4 (en) * 2017-08-31 2021-04-07 Green Cross Corporation PROCESS FOR PURIFYING A SULFATASE PROTEIN
CN111699249A (zh) * 2017-12-19 2020-09-22 夏尔人类遗传性治疗公司 纯化的芳基硫酸酯酶a及其组合物
WO2019150192A1 (en) * 2018-02-02 2019-08-08 Enzyvant Therapeutics Gmbh Methods for treating farber disease
MX2020010724A (es) * 2018-04-12 2020-11-06 Amgen Inc Metodos para preparar composiciones proteicas estables.
CN112082832B (zh) * 2019-06-12 2022-03-29 华南理工大学 一种保存城市污水中硫酸酯结合体和葡萄糖苷醛酸结合体的方法
KR102286892B1 (ko) * 2019-07-08 2021-08-06 삼천당제약주식회사 안과용 단백질 제제의 정제방법
CN110632052A (zh) * 2019-10-25 2019-12-31 山西师范大学 土壤芳基硫酸酯酶活性的荧光光谱检测法
AU2020401034B2 (en) * 2019-12-12 2024-08-29 Eli Lilly And Company Methods for viral inactivation by environmentally compatible detergents
CN112759643B (zh) * 2021-03-17 2023-05-30 华兰生物工程股份有限公司 一种血清白蛋白的脱脂方法
CN116693659B (zh) * 2023-07-11 2025-03-28 浙江大学 一种分离重组人血白蛋白的两步混合模式层析方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4314997A (en) 1980-10-06 1982-02-09 Edward Shanbrom Purification of plasma protein products
US4315919A (en) 1980-10-06 1982-02-16 Edward Shanbrom Depyrogenation process
US4764369A (en) 1983-07-14 1988-08-16 New York Blood Center Inc. Undenatured virus-free biologically active protein derivatives
CA2041280A1 (en) * 1990-05-10 1991-11-11 Yosuke Sawada Arylsulfatase
NO960163D0 (no) 1996-01-15 1996-01-15 Thomas Berg Mutasjonsdeteksjon av bovin
DE69901536T2 (de) 1998-01-27 2003-01-16 Hemebiotech A/S, Hellerod Behandlung von akuter intermittierender porphyria oder anderen porphyrischen krankheiten
IL140155A (en) 1998-06-09 2005-12-18 Statens Seruminstitut Process for producing immunoglobulins for intravenous administration and other immunoglobulin products
DK2270044T3 (en) 1998-06-09 2015-01-26 Csl Behring Ag Liquid immunoglobulin G (IgG) product
AUPQ026799A0 (en) 1999-05-10 1999-06-03 Csl Limited Method of increasing protein stability by removing immunoglobulin aggregates
JP2003505057A (ja) 1999-07-27 2003-02-12 ヘム−バイオテック エイ/エス rhPBGDの製造及び急性間欠性ポルフィリン症(AIP)及び他のポルフィリン症の患者を処置するための新規な治療方法
US6812339B1 (en) 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
CA2429210A1 (en) 2000-11-15 2002-05-23 Jason C. Goodrick Expression system for recombinant proteins
WO2002099092A2 (en) 2001-06-07 2002-12-12 Hemebiotech A/S Production of recombinant human lysosomal alpha-mannosidase
AU2002317700A1 (en) 2001-06-07 2002-12-16 Hemebiotech A/S Production of recombinant human arylsulfatase a
EP1402014A1 (en) 2001-06-29 2004-03-31 Hemebiotech A/S A process for purification of recombinant porphobilinogen deaminase
US7232670B2 (en) 2001-09-28 2007-06-19 St. Jude Children's Research Hospital Targeting proteins to cells expressing mannose receptors via expression in insect cells
WO2003057179A2 (en) 2002-01-11 2003-07-17 Biomarin Pharmaceutical, Inc. Use of p97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes
WO2003066669A2 (en) 2002-02-04 2003-08-14 Millipore Corporation Process for removing protein aggregates and virus from a protein solution
EP1713904B1 (en) * 2004-01-30 2016-06-29 Shire Pharmaceuticals Ireland Limited Production and purification of recombinant arylsulfatase a
WO2005094874A1 (en) 2004-04-01 2005-10-13 Zymenex A/S Medical use of alpha-mannosidase
US20060051347A1 (en) 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
HUE042402T2 (hu) 2006-04-04 2019-06-28 Chiesi Farm Spa Eljárás polipeptid töményítésére
BRPI0919879A2 (pt) * 2008-10-29 2016-02-16 Wyeth Llc métodos para purificação de moléculas de ligação a antígeno de domínio único
US8945895B2 (en) * 2009-07-31 2015-02-03 Baxter International Inc. Methods of purifying recombinant ADAMTS13 and other proteins and compositions thereof
HRP20191923T1 (hr) 2010-06-25 2020-01-10 Shire Human Genetic Therapies, Inc. Postupci i sastavi za isporuku arilsulfataze a u cns
LT2588130T (lt) 2010-06-25 2016-12-12 Shire Human Genetic Therapies, Inc. Terapinės priemonės pristatymas cns
GB201012603D0 (en) * 2010-07-27 2010-09-08 Ucb Pharma Sa Protein purification
CN112126634A (zh) 2013-01-09 2020-12-25 夏尔人类遗传性治疗公司 含用于纯化芳基硫酸酯酶a的方法

Similar Documents

Publication Publication Date Title
JP2016504040A5 (enExample)
EP2553095B1 (en) A process for purifying vitamin K dependent proteins such as coagulation factor IX
JP6836562B2 (ja) 治療タンパク質の精製方法
RU2647835C2 (ru) Стабилизатор для гиалуронидазы и жидкая композиция, содержащая гиалуронидазу
WO2009156430A1 (en) A process of purifying coagulation factor viii
JP2014501251A (ja) トランスジェニックイネの子実からヒト血清アルブミンを精製する方法
JPH10506924A (ja) 動物性タンパク質を含まないエリトロポイエチンの製造のための方法
JP7086601B2 (ja) 組換えtnk-tpa(テネクテプラーゼ)の単離及び商業生産のための新規精製方法
EP2343370B1 (en) A throbin-like enzyme of agkistrodon acutus
CN102924562A (zh) 一种人凝血因子ⅷ的干热处理稳定剂及其用途
JP4772905B2 (ja) アンチトロンビン組成物の製造方法
CN106349387A (zh) 一种从Cohn组分Ⅳ沉淀中纯化α1‑抗胰蛋白酶的方法
US9868762B2 (en) Method for purifying virus-like particles (VLP)
JP2019528242A5 (enExample)
KR102528707B1 (ko) 고순도의 히알루로니다제 정제 방법
HUE027724T2 (hu) Eljárás G-CSF tisztítására
CN104854122A (zh) 重组人半乳糖脑苷脂-β-半乳糖苷酶(rhGALC)的纯化
DE69719382T2 (de) VERFAHREN ZUR HERSTELLUNG VON rDSPA Alpha1
CN115386564B (zh) 一种尿激酶的纯化方法
CN105541994B (zh) 一种血小板生成素或其变体或衍生物的纯化方法
JP2722143B2 (ja) トリプシンインヒビター含有凍結乾燥製剤
CN106011116A (zh) 一种人凝血酶的制备方法
JP2861655B2 (ja) ヒト尿性トリプシンインヒビター含有液状製剤及びその製造方法
JP2722140B2 (ja) ヒト尿性トリプシンインヒビターの製造方法
HK40007788A (en) Separation of fibrinogen, fviii and/or vwf from plasma proteases by hcic